569 related articles for article (PubMed ID: 33952230)
1. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.
Gray SG
BMC Pulm Med; 2021 May; 21(1):148. PubMed ID: 33952230
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for immunotherapy in malignant pleural mesothelioma?
Tartarone A; Lerose R; Aieta M
Med Oncol; 2018 May; 35(7):98. PubMed ID: 29845408
[TBL] [Abstract][Full Text] [Related]
3. Targeting immune checkpoints: New opportunity for mesothelioma treatment?
Marcq E; Pauwels P; van Meerbeeck JP; Smits EL
Cancer Treat Rev; 2015 Dec; 41(10):914-24. PubMed ID: 26433514
[TBL] [Abstract][Full Text] [Related]
4. Emerging biological therapies for the treatment of malignant pleural mesothelioma.
Davis AP; Kao SC; Clarke SJ; Boyer M; Pavlakis N
Expert Opin Emerg Drugs; 2021 Jun; 26(2):179-192. PubMed ID: 33945357
[No Abstract] [Full Text] [Related]
5. New therapeutic strategies for malignant pleural mesothelioma.
Bonelli MA; Fumarola C; La Monica S; Alfieri R
Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
[TBL] [Abstract][Full Text] [Related]
6. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT; Egbune C
Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
[TBL] [Abstract][Full Text] [Related]
7. Malignant Mesothelioma: Has Anything Changed?
Kim RY; Sterman DH; Haas AR
Semin Respir Crit Care Med; 2019 Jun; 40(3):347-360. PubMed ID: 31525810
[TBL] [Abstract][Full Text] [Related]
8. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
9. Tremelimumab for the treatment of malignant mesothelioma.
Guazzelli A; Hussain M; Krstic-Demonacos M; Mutti L
Expert Opin Biol Ther; 2015; 15(12):1819-29. PubMed ID: 26560442
[TBL] [Abstract][Full Text] [Related]
10. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
Zeltsman M; Dozier J; McGee E; Ngai D; Adusumilli PS
Transl Res; 2017 Sep; 187():1-10. PubMed ID: 28502785
[TBL] [Abstract][Full Text] [Related]
11. Updates in the diagnosis and treatment of malignant pleural mesothelioma.
Katzman D; Sterman DH
Curr Opin Pulm Med; 2018 Jul; 24(4):319-326. PubMed ID: 29553973
[TBL] [Abstract][Full Text] [Related]
12. [Not Available].
Mignard X; Chaabane N; Fallet V; Wislez M
Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
[TBL] [Abstract][Full Text] [Related]
13. Advances in treatment of mesothelioma.
Maggioni C; Barletta G; Rijavec E; Biello F; Gualco E; Grossi F
Expert Opin Pharmacother; 2016 Jun; 17(9):1197-205. PubMed ID: 27055148
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.
Mankor JM; Disselhorst MJ; Poncin M; Baas P; Aerts JGJV; Vroman H
EBioMedicine; 2020 Dec; 62():103040. PubMed ID: 33166791
[TBL] [Abstract][Full Text] [Related]
15. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
Wong RM; Ianculescu I; Sharma S; Gage DL; Olevsky OM; Kotova S; Kostic MN; Grundfest WS; Hou D; Cameron RB
Am J Respir Cell Mol Biol; 2014 May; 50(5):870-5. PubMed ID: 24450537
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F
Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722
[TBL] [Abstract][Full Text] [Related]
18. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
20. [Advances in Immunotherapy for Malignant Pleural Mesothelioma].
Chi Y; Liu Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 Apr; 25(4):259-265. PubMed ID: 35477190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]